GET THE APP

..

Pharmacoeconomics: Open Access

ISSN: 2472-1042

Open Access

Volume 2, Issue 1 (2017)

Review Article Pages: 1 - 6

A Critical Review of Economic Evaluations of Trastuzumab in the Treatment of Early Stage HER2 Positive Breast Cancer

Quynh-Nga Thi Nguyen, Hoa Quoc Nguyen and Ciaran O’Neill

DOI: 10.4172/2472-1042.1000111

Eleven years after Trastuzumab was approved for use in the treatment of early stage human epidermal growth factor receptor positive breast cancer (HER2+) its clinical benefit has been demonstrated in short and long term follow up studies. The cost-effectiveness of the therapy in this context remains the subject of debate with a wide range of Incremental Cost Effectiveness Ratios (ICERs) reported in the literature. While several reviews of the literature have been undertaken these have not provided a critical analysis of the factors that might underlie this heterogeneity. In this review we provide a critical overview of the literature and discuss potential sources of heterogeneity in reported ICERs. We identify gaps in the current literature and provide a rationale for filling these gaps.

arrow_upward arrow_upward